{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:26:02Z","timestamp":1789874762958,"version":"4.0.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SF4522N"],"award-info":[{"award-number":["1SF4522N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["11A7320N"],"award-info":[{"award-number":["11A7320N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["18B2122N"],"award-info":[{"award-number":["18B2122N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G097118N"],"award-info":[{"award-number":["G097118N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0B2120N"],"award-info":[{"award-number":["G0B2120N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G099922N"],"award-info":[{"award-number":["G099922N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G056822N"],"award-info":[{"award-number":["G056822N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G059223N"],"award-info":[{"award-number":["G059223N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004497","name":"Onderzoeksraad, KU Leuven","doi-asserted-by":"publisher","award":["C14\/20\/117"],"award-info":[{"award-number":["C14\/20\/117"]}],"id":[{"id":"10.13039\/501100004497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40265-023-01863-y","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T10:17:45Z","timestamp":1681726665000},"page":"649-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Innovation in Targeted Intra-articular Therapies for Osteoarthritis"],"prefix":"10.1007","volume":"83","author":[{"given":"Reem","family":"Assi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Quintiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Monteagudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-3092","authenticated-orcid":false,"given":"Rik J.","family":"Lories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"issue":"6","key":"1863_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jama.2020.22171","volume":"325","author":"JN Katz","year":"2021","unstructured":"Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568\u201378.","journal-title":"JAMA"},{"issue":"2","key":"1863_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.berh.2018.10.007","volume":"32","author":"TW O'Neill","year":"2018","unstructured":"O\u2019Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol. 2018;32(2):312\u201326.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1863_CR3","unstructured":"OARSI White Paper\u2014Osteoarthritis as a serious disease. 2016. https:\/\/www.oarsi.org\/sites\/default\/files\/docs\/2016\/oarsi_white_paper_oa-serious-disease.pdf. Accessed 26 Feb 2023."},{"issue":"8","key":"1863_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-217050","volume":"79","author":"Z Jin","year":"2020","unstructured":"Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis. 2020;79(8):1014\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1863_CR5","unstructured":"Osteoarthritis: Structural Endpoints for the Development of Drugs. U.S. Food and Drug Administration; 2019."},{"issue":"1","key":"1863_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/M14-1231","volume":"162","author":"RR Bannuru","year":"2015","unstructured":"Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46\u201354.","journal-title":"Ann Intern Med"},{"issue":"378","key":"1863_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069722","volume":"6","author":"TV Pereira","year":"2022","unstructured":"Pereira TV, J\u00fcni P, Saadat P, Xing D, Yao L, Bobos P, et al. Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. BMJ. 2022;6(378): e069722.","journal-title":"BMJ"},{"issue":"1","key":"1863_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","volume":"21","author":"F Berenbaum","year":"2013","unstructured":"Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr Cartil. 2013;21(1):16\u201321.","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"1863_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13075-017-1229-9","volume":"19","author":"A Mathiessen","year":"2017","unstructured":"Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017;19(1):18.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1863_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41584-022-00749-9","volume":"18","author":"E Sanchez-Lopez","year":"2022","unstructured":"Sanchez-Lopez E, Coras R, Torres A, Lane NE, Guma M. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol. 2022;18(5):258\u201375.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1863_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.arth.2020.09.022","volume":"36","author":"M Blankstein","year":"2021","unstructured":"Blankstein M, Lentine B, Nelms NJ. Common practices in intra-articular corticosteroid injection for the treatment of knee osteoarthritis: a survey of the American Association of hip and knee surgeons membership. J Arthroplasty. 2021;36(3):845\u201350.","journal-title":"J Arthroplasty"},{"issue":"2","key":"1863_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220\u201333.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1863_CR13","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578\u201389.","journal-title":"Osteoarthr Cartil"},{"issue":"12","key":"1863_CR14","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"KM Jordan","year":"2003","unstructured":"Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1863_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2018-213826","volume":"78","author":"M Kloppenburg","year":"2019","unstructured":"Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1863_CR16","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00256-021-03815-7","volume":"50","author":"RD Boutin","year":"2021","unstructured":"Boutin RD, Pai J, Meehan JP, Newman JS, Yao L. Rapidly progressive idiopathic arthritis of the hip: incidence and risk factors in a controlled cohort study of 1471 patients after intra-articular corticosteroid injection. Skelet Radiol. 2021;50(12):2449\u201357.","journal-title":"Skelet Radiol"},{"issue":"8","key":"1863_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/art.42118","volume":"74","author":"A Latourte","year":"2022","unstructured":"Latourte A, Rat AC, Omorou A, Ngueyon-Sime W, Eymard F, Sellam J, et al. Do glucocorticoid injections increase the risk of knee osteoarthritis progression over 5 years? Arthritis Rheumatol. 2022;74(8):1343\u201351.","journal-title":"Arthritis Rheumatol"},{"issue":"19","key":"1863_CR18","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.2017.5283","volume":"317","author":"TE McAlindon","year":"2017","unstructured":"McAlindon TE, LaValley MP, Harvey WF, Price LL, Driban JB, Zhang M, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;317(19):1967\u201375.","journal-title":"JAMA"},{"key":"1863_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pmrj.12853","author":"RA Sanguino","year":"2022","unstructured":"Sanguino RA, Sood V, Santiago KA, Cheng J, Casey E, Mintz D, et al. Prevalence of rapidly progressive osteoarthritis of the hip following intra-articular steroid injections. PM R. 2022. https:\/\/doi.org\/10.1002\/pmrj.12853.","journal-title":"PM R"},{"issue":"6","key":"1863_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.joca.2019.01.007","volume":"27","author":"C Zeng","year":"2019","unstructured":"Zeng C, Lane NE, Hunter DJ, Wei J, Choi HK, McAlindon TE, et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthr Cartil. 2019;27(6):855\u201362.","journal-title":"Osteoarthr Cartil"},{"issue":"11","key":"1863_CR21","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1007\/s00296-011-2188-0","volume":"32","author":"U Yavuz","year":"2012","unstructured":"Yavuz U, S\u00f6k\u00fcc\u00fc S, Albayrak A, Ozt\u00fcrk K. Efficacy comparisons of the intraarticular steroidal agents in the patients with knee osteoarthritis. Rheumatol Int. 2012;32(11):3391\u20136.","journal-title":"Rheumatol Int"},{"issue":"2","key":"1863_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10067-003-0841-z","volume":"23","author":"D Pyne","year":"2004","unstructured":"Pyne D, Ioannou Y, Mootoo R, Bhanji A. Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Clin Rheumatol. 2004;23(2):116\u201320.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"1863_CR23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.pmrj.2018.01.002","volume":"10","author":"DM Cushman","year":"2018","unstructured":"Cushman DM, Bruno B, Christiansen J, Schultz A, McCormick ZL. Efficacy of injected corticosteroid type, dose, and volume for pain in large joints: a narrative review. PM R. 2018;10(7):748\u201357.","journal-title":"PM R"},{"key":"1863_CR24","doi-asserted-by":"crossref","unstructured":"Buyuk AF, Kilinc E, Camurcu IY, Camur S, Ucpunar H, Kara A. Compared efficacy of intra-articular injection of methylprednisolone and triamcinolone. Acta Ortop Bras. 2017;25(5):206\u20138.","DOI":"10.1590\/1413-785220172505172581"},{"issue":"9","key":"1863_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3899\/jrheum.150297","volume":"42","author":"AB Lomonte","year":"2015","unstructured":"Lomonte AB, de Morais MG, de Carvalho LO, Zerbini CA. Efficacy of triamcinolone hexacetonide versus methylprednisolone acetate intraarticular injections in knee osteoarthritis: a randomized, double-blinded, 24-week study. J Rheumatol. 2015;42(9):1677\u201384.","journal-title":"J Rheumatol"},{"issue":"1","key":"1863_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-019-0140-z","volume":"6","author":"AI Spitzer","year":"2019","unstructured":"Spitzer AI, Richmond JC, Kraus VB, Gomoll A, Jones DG, Huffman KM, et al. Safety and efficacy of repeat administration of triamcinolone acetonide extended-release in osteoarthritis of the knee: a phase 3b, open-label study. Rheumatol Ther. 2019;6(1):109\u201324.","journal-title":"Rheumatol Ther."},{"key":"1863_CR27","unstructured":"Baraf H, Lattermann C, Jones D, Conaghan P, Lufkin J, Johnson J, et al. Effectiveness of FX006 intra-articular injection in patients with knee osteoarthritis who present with and without clinical inflammation at baseline: a pooled analysis of data from 3 double-blind, randomized, parallel-group clinical trials. Am Coll Rheumato. 2017;69(10)."},{"issue":"8","key":"1863_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.2106\/JBJS.17.00154","volume":"100","author":"PG Conaghan","year":"2018","unstructured":"Conaghan PG, Hunter DJ, Cohen SB, Kraus VB, Berenbaum F, Lieberman JR, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J Bone Jt Surg Am. 2018;100(8):666\u201377.","journal-title":"J Bone Jt Surg Am"},{"key":"1863_CR29","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1016\/j.joca.2021.02.378","volume":"29","author":"NA Segal","year":"2021","unstructured":"Segal NA, Kothari MD. Interim results: the effect of intra-articular extended-release triamcinolone acetonide on OARSI-recommended physical performance measures in adults with bilateral symptomatic knee OA. Osteoarthr Cartil. 2021;29:S287\u20138.","journal-title":"Osteoarthr Cartil"},{"key":"1863_CR30","doi-asserted-by":"crossref","unstructured":"Malone A, Price J, Price N, Peck V, Getgood A, Petrella R, et al. Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: a randomized, double-blind, placebo-controlled phase 1 trial. Osteoarthr Cartil Open. 2021;3(4).","DOI":"10.1016\/j.ocarto.2021.100213"},{"issue":"1","key":"1863_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-022-02739-4","volume":"24","author":"DJ Hunter","year":"2022","unstructured":"Hunter DJ, Chang CC, Wei JC, Lin HY, Brown C, Tai TT, et al. TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study. Arthritis Res Ther. 2022;24(1):52.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1863_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/1947603517703732","volume":"9","author":"L Hangody","year":"2018","unstructured":"Hangody L, Szody R, Lukasik P, Zgadzaj W, L\u00e9n\u00e1rt E, Dokoupilova E, et al. Intraarticular injection of a cross-linked sodium hyaluronate combined with triamcinolone hexacetonide (cingal) to provide symptomatic relief of osteoarthritis of the knee: a randomized, double-blind, placebo-controlled multicenter clinical trial. Cartilage. 2018;9(3):276\u201383.","journal-title":"Cartilage"},{"key":"1863_CR33","unstructured":"Healio. Anika Therapeutics obtains CE mark for Cingal to treat OA knee pain [media release]. 2016. https:\/\/www.healio.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR34","unstructured":"Healio. Health Canada approves CINGAL as medical device to treat knee OA pain [media release]. 2015. https:\/\/www.healio.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR35","unstructured":"Fierce Biotech. Anika\u2019s combo arthritis drug Cingal flunks phase 3 test [media release]. 2018. https:\/\/www.fiercebiotech.com\/. Accessed 15 Mar 2023."},{"issue":"1","key":"1863_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","volume":"7","author":"M Kapoor","year":"2011","unstructured":"Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"1863_CR37","doi-asserted-by":"publisher","first-page":"5706359","DOI":"10.1155\/2016\/5706359","volume":"2016","author":"S Takano","year":"2016","unstructured":"Takano S, Uchida K, Miyagi M, Inoue G, Fujimaki H, Aikawa J, et al. Nerve growth factor regulation by TNF-\u03b1 and IL-1\u03b2 in synovial macrophages and fibroblasts in osteoarthritic mice. J Immunol Res. 2016;2016:5706359.","journal-title":"J Immunol Res"},{"issue":"28","key":"1863_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021131","volume":"99","author":"A Vasudeva","year":"2020","unstructured":"Vasudeva A, Yadav SL, Nanda S, Sahu S. Assessment of pain and structure after an intra-articular injection of adalimumab in osteoarthritis of the knee: a case report. Medicine (Baltimore). 2020;99(28): e21131.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1863_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0300060517723182","volume":"46","author":"J Wang","year":"2018","unstructured":"Wang J. Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. J Int Med Res. 2018;46(1):326\u201334.","journal-title":"J Int Med Res"},{"issue":"8","key":"1863_CR40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00296-009-0872-0","volume":"29","author":"A Fioravanti","year":"2009","unstructured":"Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int. 2009;29(8):961\u20135.","journal-title":"Rheumatol Int"},{"key":"1863_CR41","doi-asserted-by":"crossref","unstructured":"Lindsley HB, Schue J, Tawfik O, Bolce R, Smith DD, Hinson G, et al. Treatment of knee osteoarthritis with intra-articular infliximab improves total WOMAC score. High baseline levels of synovital cellularity predict improvement. Ann Rheum Dis. 2012;71(3):417.","DOI":"10.1136\/annrheumdis-2012-eular.2761"},{"issue":"5","key":"1863_CR42","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3349\/ymj.2015.56.5.1379","volume":"56","author":"S Ohtori","year":"2015","unstructured":"Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, et al. Efficacy of direct injection of etanercept into knee joints for pain in moderate and severe knee osteoarthritis. Yonsei Med J. 2015;56(5):1379\u201383.","journal-title":"Yonsei Med J"},{"issue":"1","key":"1863_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41598-018-36500-2","volume":"9","author":"M Lv","year":"2019","unstructured":"Lv M, Zhou Y, Polson SW, Wan LQ, Wang M, Han L, et al. Identification of chondrocyte genes and signaling pathways in response to acute joint inflammation. Sci Rep. 2019;9(1):93.","journal-title":"Sci Rep"},{"key":"1863_CR44","unstructured":"Schieker M, Mindeholm L, Praestgaard J, Scotti C, Solomon D, Thuren T, et al. Interleukin-1\u03b2 inhibition with canakinumab associates with reduced rates of total hip and knee replacement (THR\/TKR) and osteoarthritis (OA) symptoms: exploratory results from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Coll Rheumatol. 2018;70(9)."},{"issue":"2","key":"1863_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cyto.2014.10.023","volume":"71","author":"S Cheleschi","year":"2015","unstructured":"Cheleschi S, Cantarini L, Pascarelli NA, Collodel G, Lucherini OM, Galeazzi M, et al. Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes. Cytokine. 2015;71(2):165\u201372.","journal-title":"Cytokine"},{"key":"1863_CR46","unstructured":"Conaghan P, Chevalier X, Mindeholm L, Schramm U, Praestgaard JSA, Roubenoff RSM. Intra-articular canakinumab (anti-interleukin-1\u03b2) for treatment of symptomatic knee osteoarthritis: a randomized, double-blind, placebo and naproxen-controlled phase II study. Am Coll of Rheumatol. 2021;73(9)."},{"issue":"7","key":"1863_CR47","first-page":"1317","volume":"32","author":"X Chevalier","year":"2005","unstructured":"Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005;32(7):1317\u201323.","journal-title":"J Rheumatol"},{"issue":"3","key":"1863_CR48","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/art.24096","volume":"61","author":"X Chevalier","year":"2009","unstructured":"Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61(3):344\u201352.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1863_CR49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.20720","volume":"41","author":"GJ Quinlan","year":"2005","unstructured":"Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"1863_CR50","first-page":"35","volume":"64","author":"R Shimonkevitz","year":"2008","unstructured":"Shimonkevitz R, Thomas G, Slone DS, Craun M, Mains C, Bar-Or D. A diketopiperazine fragment of human serum albumin modulates T-lymphocyte cytokine production through rap1. J Trauma. 2008;64(1):35\u201341.","journal-title":"J Trauma"},{"issue":"2","key":"1863_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087910","volume":"9","author":"D Bar-Or","year":"2014","unstructured":"Bar-Or D, Salottolo KM, Loose H, Phillips MJ, McGrath B, Wei N, et al. A randomized clinical trial to evaluate two doses of an intra-articular injection of LMWF-5A in adults with pain due to osteoarthritis of the knee. PLoS ONE. 2014;9(2): e87910.","journal-title":"PLoS ONE"},{"key":"1863_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13037-018-0158-0","volume":"12","author":"K Salottolo","year":"2018","unstructured":"Salottolo K, Cole B, Bar-Or D. Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial. Patient Saf Surg. 2018;12:11.","journal-title":"Patient Saf Surg"},{"issue":"1","key":"1863_CR53","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3928\/01477447-20171114-05","volume":"41","author":"B Cole","year":"2018","unstructured":"Cole B, McGrath B, Salottolo K, Bar-Or D. LMWF-5A for the treatment of severe osteoarthritis of the knee: integrated analysis of safety and efficacy. Orthopedics. 2018;41(1):e77\u201383.","journal-title":"Orthopedics"},{"key":"1863_CR54","unstructured":"PR Newswire. Ampio pharmaceuticals, inc. Releases positive phase 3 data analysis for ampion\u2122 targeting severe osteoarthritis of the knee (oak) [media release]. 2022. https:\/\/www.prnewswire.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR55","unstructured":"Trivano. Ampio provides regulatory update [media release]. 2022. https:\/\/www.trivano.com\/. Accessed 15 Mar 2023."},{"issue":"8","key":"1863_CR56","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00011-007-7204-1","volume":"57","author":"S Meini","year":"2008","unstructured":"Meini S, Maggi CA. Knee osteoarthritis: a role for bradykinin? Inflamm Res. 2008;57(8):351\u201361.","journal-title":"Inflamm Res"},{"issue":"1","key":"1863_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/ard.2007.080382","volume":"68","author":"IH Song","year":"2009","unstructured":"Song IH, Althoff CE, Hermann KG, Scheel AK, Knetsch T, Burmester GR, et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann Rheum Dis. 2009;68(1):75\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1863_CR58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.joca.2016.08.010","volume":"25","author":"K Grothe","year":"2017","unstructured":"Grothe K, Flechsenhar K, Paehler T, Ritzeler O, Beninga J, Saas J, et al. I\u03baB kinase inhibition as a potential treatment of osteoarthritis\u2014results of a clinical proof-of-concept study. Osteoarthr Cartil. 2017;25(1):46\u201352.","journal-title":"Osteoarthr Cartil"},{"issue":"9","key":"1863_CR59","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/art.41725","volume":"73","author":"Y Nishida","year":"2021","unstructured":"Nishida Y, Kano K, Nobuoka Y, Seo T. Efficacy and safety of diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase III trial in Japan. Arthritis Rheumatol. 2021;73(9):1646\u201355.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1863_CR60","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/joca.2002.0514","volume":"10","author":"JL Ellsworth","year":"2002","unstructured":"Ellsworth JL, Berry J, Bukowski T, Claus J, Feldhaus A, Holderman S, et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthr Cartil. 2002;10(4):308\u201320.","journal-title":"Osteoarthr Cartil"},{"issue":"21","key":"1863_CR61","doi-asserted-by":"publisher","first-page":"20509","DOI":"10.1074\/jbc.M410148200","volume":"280","author":"D Davidson","year":"2005","unstructured":"Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G, et al. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem. 2005;280(21):20509\u201315.","journal-title":"J Biol Chem"},{"issue":"11","key":"1863_CR62","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.joca.2017.08.004","volume":"25","author":"A Gigout","year":"2017","unstructured":"Gigout A, Guehring H, Froemel D, Meurer A, Ladel C, Reker D, et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthr Cartil. 2017;25(11):1858\u201367.","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"1863_CR63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.joca.2005.03.003","volume":"13","author":"EE Moore","year":"2005","unstructured":"Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthr Cartil. 2005;13(7):623\u201331.","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"1863_CR64","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12967-017-1356-8","volume":"15","author":"D Reker","year":"2017","unstructured":"Reker D, Kjelgaard-Petersen CF, Siebuhr AS, Michaelis M, Gigout A, Karsdal MA, et al. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. J Transl Med. 2017;15(1):250.","journal-title":"J Transl Med"},{"issue":"10","key":"1863_CR65","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/jor.24048","volume":"36","author":"ML Sennett","year":"2018","unstructured":"Sennett ML, Meloni GR, Farran AJE, Guehring H, Mauck RL, Dodge GR. Sprifermin treatment enhances cartilage integration in an in vitro repair model. J Orthop Res. 2018;36(10):2648\u201356.","journal-title":"J Orthop Res"},{"issue":"7","key":"1863_CR66","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.38614","volume":"66","author":"LS Lohmander","year":"2014","unstructured":"Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(7):1820\u201331.","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"1863_CR67","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2019.14735","volume":"322","author":"MC Hochberg","year":"2019","unstructured":"Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA. 2019;322(14):1360\u201370.","journal-title":"JAMA"},{"key":"1863_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219181","author":"F Eckstein","year":"2021","unstructured":"Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, et al. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219181.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1863_CR69","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.semarthrit.2021.03.005","volume":"51","author":"H Guehring","year":"2021","unstructured":"Guehring H, Moreau F, Daelken B, Ladel C, Guenther O, Bihlet AR, et al. The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. Semin Arthritis Rheum. 2021;51(2):450\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1863_CR70","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.joca.2019.05.006","volume":"27","author":"V Deshmukh","year":"2019","unstructured":"Deshmukh V, O\u2019Green AL, Bossard C, Seo T, Lamangan L, Ibanez M, et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthr Cartil. 2019;27(9):1347\u201360.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"1863_CR71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40744-020-00205-8","volume":"7","author":"RJ Lories","year":"2020","unstructured":"Lories RJ, Monteagudo S. Review article: is wnt signaling an attractive target for the treatment of osteoarthritis? Rheumatol Ther. 2020;7(2):259\u201370.","journal-title":"Rheumatol Ther."},{"issue":"1","key":"1863_CR72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.joca.2017.08.015","volume":"26","author":"V Deshmukh","year":"2018","unstructured":"Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2018;26(1):18\u201327.","journal-title":"Osteoarthr Cartil"},{"issue":"10","key":"1863_CR73","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/art.41315","volume":"72","author":"Y Yazici","year":"2020","unstructured":"Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, et al. Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and wnt pathway modulator for the treatment of knee osteoarthritis: a phase II randomized trial. Arthritis Rheumatol. 2020;72(10):1694\u2013706.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1863_CR74","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","volume":"29","author":"Y Yazici","year":"2021","unstructured":"Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, et al. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthr Cartil. 2021;29(5):654\u201366.","journal-title":"Osteoarthr Cartil"},{"key":"1863_CR75","doi-asserted-by":"crossref","unstructured":"Yazici Y, Swearingen C, Ghandehari H, Britt J, Simsek I, Fineman M, et al. A phase 2, 104-week study of repeat lorecivivint injections evaluating safety, efficacy, and bone health utilizing quantitative computed tomography (qCT) in knee osteoarthritis (OA-06). Am Coll Rheumatol. 2022;74(9).","DOI":"10.1016\/j.joca.2023.01.163"},{"key":"1863_CR76","unstructured":"Yazici Y, Swearingen C, Ghandehari H, Britt J, Simsek I, Fineman M, et al. A phase 3, 56-week, multicenter, randomized, double-blind, placebo controlled trial (OA-11) to evaluate the efficacy and safety of a single injection of lorecivivint injected in the target knee joint of moderate to severe osteoarthritis participants. Am Coll Rheumatol. 2022;74(9)."},{"key":"1863_CR77","unstructured":"Yazici Y, Swearingen C, Ghandehari H, Lopez V, Simsek I, Fineman M, et al. A phase 3, 28-week, multicenter, randomized, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects. Am Coll Rheumatol. 2022;74(9)."},{"issue":"12","key":"1863_CR78","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1038\/s41591-022-02059-9","volume":"28","author":"N Gerwin","year":"2022","unstructured":"Gerwin N, Scotti C, Halleux C, Fornaro M, Elliott J, Zhang Y, et al. Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat Med. 2022;28(12):2633\u201345.","journal-title":"Nat Med"},{"issue":"1","key":"1863_CR79","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/j.joca.2022.02.276","volume":"30","author":"F Saxer","year":"2022","unstructured":"Saxer F, Laurent D, Scotti C, Juras V, Hacker S, Cole B, et al. Cartilage regeneration after treatment with LNA043, A novel disease-modifying osteoarthritis drug candidate: results from an imaging-based proof-of-concept trial in patients with focal articular cartilage lesions in the knee. Osteoarthr Cartil. 2022;30(1):S206\u20137.","journal-title":"Osteoarthr Cartil"},{"key":"1863_CR80","doi-asserted-by":"crossref","unstructured":"Trattnig S, Scotti C, Laurent D, Juras V, Hacker S, Cole B, et al. Anabolic effect of LNA043, a novel disease modifying osteoarthritis drug candidate: results from an imaging-based proof-of-concept trial in patients with focal articular cartilage lesions. Ann Rheum Dis. 2021;80:363.","DOI":"10.1136\/annrheumdis-2021-eular.447"},{"key":"1863_CR81","unstructured":"Novartis. Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee [media release]. 2021. https:\/\/www.novartis.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR82","unstructured":"A clinical trial to learn about the safety of trial drug LRX712 for people with osteoarthritis. Clinical trial results summary. 2020."},{"issue":"6082","key":"1863_CR83","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1126\/science.1215157","volume":"336","author":"K Johnson","year":"2012","unstructured":"Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, et al. A stem cell-based approach to cartilage repair. Science. 2012;336(6082):717\u201321.","journal-title":"Science"},{"key":"1863_CR84","doi-asserted-by":"crossref","unstructured":"Johnson KA, Woods AK, Joseph SB, Chatterjee AK, Zhu S, Wisler J, et al. Development of KA34 as a cartilage regenerative therapy for osteoarthritis. Osteoarthr Cartil. 2020;28(1):S518.","DOI":"10.1016\/j.joca.2020.02.814"},{"key":"1863_CR85","unstructured":"Johnson K. Evaluation of the safety and tolerability of KA34 in a phase 1, double-blind, dose escalation trial in patients with knee osteoarthritis. CLIN2-10388. https:\/\/www.cirm.ca.gov\/. Accessed 15 Mar 2023."},{"key":"1863_CR86","unstructured":"SCRIPPS RESEARCH. KA34: reversing osteoarthritis [media release]. 2019. https:\/\/magazine.scripps.edu\/. Accessed 15 Mar 2023."},{"key":"1863_CR87","unstructured":"Middleton-Hardie CA, Aberman H, Simon T, Alliston T, Mortazavi A, Rosen DM. AC-100 promotes cartilage defect repair in vivo and chondrocyte differentiation and function in vitro. In: 56th annual meeting of the orthopaedic research society 2010; abstract 974."},{"issue":"1","key":"1863_CR88","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13075-021-02622-8","volume":"23","author":"D McGuire","year":"2021","unstructured":"McGuire D, Bowes M, Brett A, Segal NA, Miller M, Rosen D, et al. Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA. Arthritis Res Ther. 2021;23(1):242.","journal-title":"Arthritis Res Ther"},{"key":"1863_CR89","doi-asserted-by":"crossref","unstructured":"McGuire D, Lane N, Segal N, Metyas S, Barthel H, Miller M, et al. TPX-100 leads to marked, sustained improvements in subjects with knee osteoarthritis: pre-clinical rationale and results of a controlled clinical trial. Osteoarthr Cartil. 2018;26(1):S243.","DOI":"10.1016\/j.joca.2018.02.502"},{"issue":"4","key":"1863_CR90","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/annrheumdis-2020-217160","volume":"80","author":"MA Bowes","year":"2020","unstructured":"Bowes MA, Kacena K, Alabas OA, Brett AD, Dube B, Bodick N, et al. Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the osteoarthritis initiative. Ann Rheum Dis. 2020;80(4):502\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1863_CR91","unstructured":"PR Newswire. Gr\u00fcnenthal acquires Mestex AG and its phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee [media release]. 2021. https:\/\/www.prnewswire.com\/. Accessed 15 Mar 2023."},{"issue":"1","key":"1863_CR92","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40265-020-01429-2","volume":"81","author":"M Iftinca","year":"2021","unstructured":"Iftinca M, Defaye M, Altier C. TRPV1-targeted drugs in development for human pain conditions. Drugs. 2021;81(1):7\u201327.","journal-title":"Drugs"},{"issue":"9","key":"1863_CR93","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/art.40894","volume":"71","author":"RM Stevens","year":"2019","unstructured":"Stevens RM, Ervin J, Nezzer J, Nieves Y, Guedes K, Burges R, et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 2019;71(9):1524\u201333.","journal-title":"Arthritis Rheumatol"},{"key":"1863_CR94","unstructured":"Centrexion Therapeutics. Centrexion therapeutics announces fast track designation granted by FDA to CNTX-4975 for treatment of knee osteoarthritis pain [media release]. 2018. https:\/\/centrexion.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR95","unstructured":"pharmaphorum. Gr\u00fcnenthal takes non-opioid pain drug resiniferatoxin into phase 3 [media release]. 2022. https:\/\/pharmaphorum.com\/. Accessed 15 Mar 2023."},{"issue":"11","key":"1863_CR96","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.joca.2019.05.028","volume":"27","author":"E Krupka","year":"2019","unstructured":"Krupka E, Jiang GL, Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthr Cartil. 2019;27(11):1599\u2013607.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"1863_CR97","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.39493","volume":"68","author":"AJ Teichtahl","year":"2016","unstructured":"Teichtahl AJ, Cicuttini FM. Editorial: pain relief in osteoarthritis: the potential for a perfect storm. Arthritis Rheumatol. 2016;68(2):270\u20133.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1863_CR98","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.39492","volume":"68","author":"MC Hochberg","year":"2016","unstructured":"Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, et al. When is osteonecrosis not osteonecrosis?: Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 2016;68(2):382\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"1863_CR99","unstructured":"Sanofi. Sanofi delivers 2018 business EPS growth of 5.1% at CER. 2019 [media release]. 2019. https:\/\/www.news.sanofi.us\/. Accessed 15 Mar 2023."},{"issue":"1","key":"1863_CR100","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/hum.2017.181","volume":"29","author":"CH Evans","year":"2018","unstructured":"Evans CH, Ghivizzani SC, Robbins PD. Gene delivery to joints by intra-articular injection. Hum Gene Ther. 2018;29(1):2\u201314.","journal-title":"Hum Gene Ther"},{"key":"1863_CR101","unstructured":"businesswire. Xalud therapeutics receives FDA fast track designation for XT-150 for the treatment of pain associated with osteoarthritis of the knee [media release]. 2021. https:\/\/www.businesswire.com\/."},{"key":"1863_CR102","unstructured":"Kelley S, Kivitz A, Senter B, Golod D, Cinar A, Martin EW, et al. Interim data from the first-in-human phase 1 trial of FX201, an intra-articular, helper-dependent adenoviral gene therapy for osteoarthritis\u2014safety, tolerability, biodistribution, and preliminary evaluation of clinical activity in 5 patients. Am Soc Gene Cell Ther. 2021;29(4):288."},{"issue":"7","key":"1863_CR103","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/jgm.1334","volume":"11","author":"JD Kay","year":"2009","unstructured":"Kay JD, Gouze E, Oligino TJ, Gouze JN, Watson RS, Levings PP, et al. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med. 2009;11(7):605\u201314.","journal-title":"J Gene Med"},{"key":"1863_CR104","doi-asserted-by":"crossref","unstructured":"Wang G, Evans CH, Benson JM, Hutt JA, Seagrave J, Wilder JA, et al. Safety and biodistribution assessment of sc-rAAV2.5IL-1Ra administered via intra-articular injection in a mono-iodoacetate-induced osteoarthritis rat model. Mol Ther Methods Clin Dev. 2016;3:15052.","DOI":"10.1038\/mtm.2015.52"},{"issue":"6","key":"1863_CR105","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/gt.2012.81","volume":"20","author":"RS Watson","year":"2013","unstructured":"Watson RS, Broome TA, Levings PP, Rice BL, Kay JD, Smith AD, et al. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. 2013;20(6):670\u20137.","journal-title":"Gene Ther"},{"issue":"1","key":"1863_CR106","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/j.joca.2022.02.208","volume":"30","author":"M Park","year":"2022","unstructured":"Park M, Collins J, Lee N, Go H-K, Shin S, Jin C, et al. Semi-quantitative and quantitative cartilage improvement after intra-articular injection of ICM-203 in canine OA model. Osteoarthr Cartil. 2022;30(1):S162\u20133.","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"1863_CR107","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.joca.2021.09.013","volume":"30","author":"JPM Vrouwe","year":"2022","unstructured":"Vrouwe JPM, Meulenberg JJM, Klarenbeek NB, Navas-Canete A, Reijnierse M, Ruiterkamp G, et al. Administration of an adeno-associated viral vector expressing interferon-beta in patients with inflammatory hand arthritis, results of a phase I\/II study. Osteoarthr Cartil. 2022;30(1):52\u201360.","journal-title":"Osteoarthr Cartil"},{"key":"1863_CR108","doi-asserted-by":"crossref","unstructured":"Cho J, Kim T, Park Y, Shin J, Kang S, Lee B. INVOSSA\u2122(TISSUEGENE-C) in patients with osteoarthritis: a phase III trial. Osteoarthr Cartil. 2016;24(1):S190.","DOI":"10.1016\/j.joca.2016.01.374"},{"key":"1863_CR109","doi-asserted-by":"crossref","unstructured":"Lee B. INVOSSA, a first-in-class of cell and gene therapy for osteoarthritis treatment: the phase III trial. Osteoarthr Cartil. 2018;26(1):S43-4.","DOI":"10.1016\/j.joca.2018.02.103"},{"key":"1863_CR110","doi-asserted-by":"crossref","unstructured":"Lew S, Cho J, Kim T, Lee M. Long-term follow-up assessment of the safety and efficacy of INVOSSA-K Inj., a novel cell mediated gene therapy for treatment of osteoarthritis. Osteoarthr Cartil; 2019;27(1):S212.","DOI":"10.1016\/j.joca.2019.02.330"},{"issue":"12","key":"1863_CR111","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.joca.2015.06.019","volume":"23","author":"JJ Cherian","year":"2015","unstructured":"Cherian JJ, Parvizi J, Bramlet D, Lee KH, Romness DW, Mont MA. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-\u03b21 in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthr Cartil. 2015;23(12):2109\u201318.","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"1863_CR112","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12891-017-1830-8","volume":"18","author":"A Guermazi","year":"2017","unstructured":"Guermazi A, Kalsi G, Niu J, Crema MD, Copeland RO, Orlando A, et al. Structural effects of intra-articular TGF-\u03b21 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial. BMC Musculoskelet Disord. 2017;18(1):461.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"1863_CR113","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/humc.2017.249","volume":"29","author":"MK Kim","year":"2018","unstructured":"Kim MK, Ha CW, In Y, Cho SD, Choi ES, Ha JK, et al. A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients. Hum Gene Ther Clin Dev. 2018;29(1):48\u201359.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"1863_CR114","unstructured":"Korea Biomedical Review. Kolon TissueGene shares to resume trading on Kosdaq from Oct.25 [media release]. 2022. https:\/\/www.koreabiomed.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR115","unstructured":"Korea Biomedical Review. Is Kolon TissueGene's Invossa set to make a comeback? [media release]. 2022. https:\/\/www.koreabiomed.com\/. Accessed 15 Mar 2023."},{"key":"1863_CR116","doi-asserted-by":"crossref","unstructured":"van der Kraan PM. Inhibition of transforming growth factor-\u03b2 in osteoarthritis. Discrepancy with reduced TGF\u03b2 signaling in normal joints. Osteoarthr Cartil Open. 2022;4(1):100238.","DOI":"10.1016\/j.ocarto.2022.100238"},{"issue":"6","key":"1863_CR117","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nm.4324","volume":"23","author":"OH Jeon","year":"2017","unstructured":"Jeon OH, Kim C, Laberge RM, Demaria M, Rathod S, Vasserot AP, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23(6):775\u201381.","journal-title":"Nat Med"},{"key":"1863_CR118","doi-asserted-by":"crossref","unstructured":"B. Hsu JV, N.E. Lane, L. Li, J. Mittal, M. An, R.-M. Laberge, J. Dananberg. Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101. Osteoarthr Cartil. 2020;28(1):S479-80.","DOI":"10.1016\/j.joca.2020.02.752"},{"key":"1863_CR119","doi-asserted-by":"crossref","unstructured":"Bachtell N, Bihlet AR, Byrjalsen I, Andersen JR, McLaughlin P. Trial design of SB-061 in osteoarthritis of the knee. The MODIFY-OA trial. Osteoarthr Cartil. 2017;25(1):S437.","DOI":"10.1016\/j.joca.2017.02.754"},{"key":"1863_CR120","unstructured":"BioSpace. Symic bio completes the MODIFY2 phase 2 trial of SB-061 for the treatment of knee osteoarthritis [media release]. 2018. https:\/\/www.biospace.com\/. Accessed 15 Mar 2023."},{"issue":"10","key":"1863_CR121","first-page":"52","volume":"14","author":"M Gotoh","year":"2014","unstructured":"Gotoh M, Nagano A, Tsukahara R, Murofushi H, Morohoshi T, Otsuka K, et al. Cyclic phosphatidic acid relieves osteoarthritis symptoms. Mol Pain. 2014;14(10):52.","journal-title":"Mol Pain"},{"issue":"1","key":"1863_CR122","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022;12(1):1567.","journal-title":"Sci Rep"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01863-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T15:03:54Z","timestamp":1684595034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01863-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":122,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1863"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01863-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"20 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Leuven Research and Development, the technology transfer office of KU Leuven, has received consultancy and speaker fees on behalf of R.J.L. from Abbvie, Amgen (Celgene), Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Biosplice Therapeutics (formerly Samumed), Viatris and UCB. The other authors declare that they have no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"R.A. and J.Q. are the recipients of PhD fellowships (1SF4522N and 11A7320N, respectively) and R.L. is the recipient of a senior clinical investigator fellowship (18B2122N) from the Flanders Research Foundation (FWO-Vlaanderen). Research on osteoarthritis in the Laboratory of Tissue Homeostasis and Disease is supported by grants from FWO-Vlaanderen (G097118N, G0B2120N, G099922N, G056822N and G059223N) and from KU Leuven (C14\/20\/117).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"R.A and J.Q contributed equally as first authors and were responsible for the literature review and first draft of the manuscript. S.M. and R.L contributed to the further development of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}